Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, Москва
Список исп. литературыСкрыть список 1. Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ 2012; 345: e7500. 2. Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin Psychiat 2010; 12: 2. 3. Martens EJ, de Jonge P, Na B et al. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease the heart and soul study. Arch Gen Psychiat 2010; 67 (7): 750–8. 4. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003; 4176: 38–50. 5. Mackintosh MA, Gatz M, Wetherell JL, Pedersen NL. A twin study of lifetime generalized anxiety disorder (GAD) in older adults: genetic and environmental influences shared by neuroticism and GAD. Twin Res Hum Genet 2006; 9 (1): 30–7. 6. Vreeburg SA, Zitman FG, van PJ et al. Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom Med 2010; 72 (4): 340–7. 7. Barlow D. Anxiety and its disorders: the nature and treatment of anxiety and panic. NY: Guilford, 1988. 8. Bandelow B, Zohar J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiat 2008; 9 (4): 248–312. 9. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2011; 14 (5): 697–710. 10. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalized anxiety disorder: systematic review and meta-analysis. BMJ 2011; 342: d1199. 11. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21 (8): 864–72. 12. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol 2013; 28 (2): 151–9. 13. Stein DJ, Ahokas A, Albarran C et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo controlled discontinuation study. J Clin Psychiat 2012; 73 (7): 1002–8. 14. Bossini L, Casolaro I, Koukouna D et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother 2012; 13 (12): 1707–17. 15. Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003; 37 (4): 133–46. 16. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004; 9 (10): 716–23. 17. Huh J, Goebert D, Takeshita J et al. Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion. CNS Dis 2011; 13: 2. 18. Zahreddine N, Richa S. Non-antidepressant treatment of generalized anxiety disorder. Curr Clin Pharmacol 2013. Epub ahead of print. 19. Meibach RC, Dunner D, Wilson LG et al. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiat 1987; 48 (9): 355–8. 20. Hofmann SG, Smits JA. Cognitive behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiat 2008; 69 (4): 621–32. 21. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006; 368 (9553): 2156–66. 22. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007; 7 (7): 769–81. 23. Wensel T, Powe K. Pregabalin for the treatment of generalized Anxiety Disorder. Ann Pharmacother 2012; 46: 424–9. 24. Di Nicola M, Martinotti G, Tedeschi D et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol 2010; 25 (3): 268–75. 25. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Exp Opin Invest Drugs 2012; 21 (7): 1019–29. 26. Micó J, Prieto R. Elucidating the mechanism of action of pregabalin: a2d as a therapeutic target in anxiety. CNS Drugs 2012; 26 (8): 637–48. 27. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiat 2003; 160: 533–40. 28. Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–9. 29. Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiat 2005; 62: 1022–30. 30. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind placebo-controlled comparison of BID vs. TID dosing. J Clin Psychopharmacol 2005; 25: 151–8. 31. Montgomery SA, Tobias K, Zornberg GL et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6 week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiat 2006; 67: 771–82. 32. Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24: 87–96. 33. Feltner D, Wittchen H, Kavoussi R et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23: 18–28. 34. Montgomery S, Chatamra K, Pauer L et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiat 2008; 193: 389–94. 35. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiat 2005; 66 (10): 1321–5. 36. Pollack MH, Simon NM, Zalta AK et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiat 2006; 59 (3): 211–5. 37. Altamura AC, Serati M, Buoli M, Dell’Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharm 2011; 26 (4): 201–5. 38. Simon NM, Connor KM, Le Beau RT et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacol (Berl) 2008; 197 (4): 675–81. 39. Rickels K, Shiovitz TM, Ramey TS et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharm 2012; 27 (3): 142–50. 40. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 2012; 26 (4): 461–70. 41. Pollack MH, Kornstein SG, Spann ME et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiat Res 2008; 42 (14): 1176–84. 42. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 2009; 24 (4): 269–75. 43. Baldwin DS, Schweizer E, Xu Y, Lyndon G. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR? Eur Neuropsychopharmacol 2012; 22 (2): 137–42. 44. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiat 2007; 40 (4): 163–8. 45. Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13 (2): 229–41. 46. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18 (6): 422–30. 47. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel g-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29 (1): 26–48. 48. Baldwin DS, Ajel K. The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiat Dis Treat 2007; 3 (2): 185–91. 49. Ogawa S, Satoh J, Arakawa A et al. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Saf 2012; 35 (10): 793–806. 50. Sjoberg G, Feychting K. Pregabalin overdose in adults and adolescents – experience in Sweden. Clin Toxicol 2010; 48 (3): 282. 51. European Medicines Agency. Pregabalin 2013. http:// www.emea.europa.eu/humandocs/Humans/EPAR/lyrica/lyrica.htm 52. Grosshans M, Mutschler J, Hermann D et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiat 2010; 167 (7): 869. 53. Gahr M, Freudenmann RW et al. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 2013; 69 (6): 1335–42. 54. Oulis P, Masdrakis VG, Karakatsanis NA et al. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharm 2008; 23 (2): 110–2. 55. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 2012; 26 (4): 461–70. 56. Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther 2012; 29 (11): 947–57. 57. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008: 25 (1): 72–90. 58. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults. http://guidance.nice.org.uk/CG113 59. Silva ML, Silva MN, Ines M. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff Resour Alloc 2013; 11 (1): 8. 60. Vera-Llonch M, Dukes E, Rejas J et al. Cost-effectiveness of pregabalin vs. venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ 2010; 11 (1): 35–44. 61. De Salas-Cansado M, Olivares JM et al. Pregabalin vs. SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clin Outcomes Res 2012; 4: 157–68. 62. Baldwin DS, Ajel K, Masdrakis V. Pregabalin for the treatment of generalized anxiety disorder: update. Neuropsychiatric Dis Treatment 2013; 9: 883–92.